Compare AbCellera Biologics Inc (ABCL) vs ACADIA Pharmaceuticals Inc. (ACAD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs ACADIA Pharmaceuticals Inc. — how do they compare? AbCellera Biologics Inc trades at $9.13 (market cap $2.99B), while ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| ABCL | ACAD | |
|---|---|---|
Market Cap | $2.99B | $5.07B |
Sector | Health | Health |
52-Week High | $9.76 | $29.41 |
52-Week Low | $2.78 | $20.06 |
Enterprise Value | $2.58B | $4.19B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →
